Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Medical technology firm Danaher Corp said on Wednesday it would separate its environmental & applied solutions (EAS) segment to create a publicly traded company.

Danaher to spin off environmental and applied solutions unit

Danaher Corp. DHR, -0.02% on Wednesday said it would spin off its Environmental & Applied Solutions segment into a separate publicly-traded company. The spin-off, expected to be completed in the fourth quarter of 2023, would help the diagnostic-tools provider become "a more focused science and technology leader committed to innovation and making a profound impact on human health," Chief Executive Rainer M.

Danaher To Spin Off Environmental Unit

WASHINGTON , Sept. 14, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced its intention to separate its Environmental & Applied Solutions segment to create an independent, publicly traded company.

Danaher Announces Intention to Separate Environmental & Applied Solutions Segment to Create an Independent, Publicly Traded Company

Oracle

Starbucks

Twitter

Twitter holds a shareholder vote on Tuesday over Elon Musk's acquisition. The August consumer price index will provide the latest inflation data.

Twitter, Starbucks, Oracle, Danaher, and Other Stocks to Watch This Week

WASHINGTON , Sept. 1, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting at Cytiva on September 15, 2022 beginning at approximately 12:00 p.m.

Danaher to Webcast Bioprocessing Investor and Analyst Meeting at Cytiva

Danaher Corporation's recent quarter earnings beat expected results by $0.40 on the bottom line and top-line beat by 7.3%, with an excellent gain over last year's results. Danaher's 80-month total return is fantastic, beating the Dow 80-month baseline by 248.06%, a slight increase from the last quarter.

Danaher: Great Total Return And With Increasing Cash Flow Allowing Growth Of The Business

Danaher (DHR) is benefiting from strength in its Life Sciences segment, acquisitions and shareholder-friendly actions despite supply-chain challenges and escalating costs.

Here's Why Investors Should Retain Danaher (DHR) Stock for Now

Danaher Corporation ( DHR , Financial) is a diversified science and technology company that designs, manufactures, and distributes professional, medical, industrial, and commercial products and services around the world. The company is a global leader in each of the following four businesses with operations in over 60 countries.

Weitz Analyst Corner: Danaher Corp

Allegion

Baker Hughes Co

nVent Electric plc

Univar

The featured stocks all trade at substantial discounts to analyst price targets.

5 Stocks Wall Street Thinks Could Soar

Abbott Labs

Costco

iShares Morningstar Value ETF

New Linde PLC

NVIDIA

Following this year's sell-off, seasoned investors are increasingly hunting for large-cap stocks to buy on the dip. For instance, the S&P 500 index and Dow Jones Industrial Average have lost 185 and 13% so far in 2022.

7 Large-Cap Stocks to Buy on the Dip

There's life after COVID-19 for Danaher, and the stock has a long pathway of growth ahead of it.

1 Conglomerate Stock You'll Be Happy You Own In 2032

BREA, Calif. , July 25, 2022 /PRNewswire/ -- Beckman Coulter, global leader in advanced diagnostics, today announced that it will partner with Massachusetts General Hospital to validate the use of the novel Monocyte Distribution Width (MDW) hematology biomarker in rapid identification of children presenting with early signs of severe illness from infection.

Beckman Coulter Partners with Mass General and BARDA to Identify Severe Pediatric Infections in Emergency Departments

U.S. stocks closed higher on Thursday, with the Nasdaq Composite jumping around 1.4%. Here is the list of some big stocks recording gains in the previous session.

Tesla, Danaher And Some Other Big Gainers From Yesterday

“Defensive” and “high quality” is what RBC Capital Markets called Danaher Corporation (NYSE:DHR) stock. In a note on Wednesday, RBC said that Danaher's leverage of only 1.7 times makes the stock attractive.

Danaher is on the verge of breakout as RBC analysts make a big call

Danaher's (DHR) second-quarter 2022 revenues increase 7.4% year over year, driven by an impressive performance across its segments.

Danaher's (DHR) Q2 Earnings & Revenues Beat, Increase Y/Y

Danaher Corporation (NYSE:DHR ) Q2 2022 Earnings Conference Call July 21, 2022 8:00 AM ET Company Participants John Bedford – Vice President-Investor Relations Rainer Blair – President and Chief Executive Officer Matt McGrew – Executive Vice President and Chief Financial Officer Conference Call Participants Rainer Blair – Bank of America Vijay Kumar – Evercore ISI Scott Davis – Melius Research Dan Brennan – Cowen Jack Meehan – Nephron Rachel Vatnsdal – JPMorgan Patrick Donnelly – Citi Operator My name is Gretchen and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation's Second Quarter 2022 Earnings Results Conference Call.

Danaher Corporation's (DHR) CEO Rainer Blair on Q2 2022 Results - Earnings Call Transcript

Danaher crushed second-quarter expectations Thursday, bolstered by strong Covid testing sales. DHR stock surged higher.

Danaher's Covid Tailwind Is In Question; Why One Analyst Isn't Worried

Danaher (DHR) delivered earnings and revenue surprises of 17.45% and 6.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Beats Q2 Earnings and Revenue Estimates

Danaher Corp (NYSE: DHR) has logged Q2 FY22 adjusted EPS of $2.76, up 12% Y/Y, surpassing the estimate of $2.35. Sales increased 7.5% to $7.75 billion, with 9.5% non-GAAP core and 8.0% non-GAAP base business core revenue growth, beating the $7.32 billion estimate.

Danaher Easily Beats Q2 Street View With Growth From Base Business; FY22 Outlook Unchanged

WASHINGTON, D.C. , July 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022.

Danaher Reports Second Quarter 2022 Results

While impressive segmental performances are expected to have aided Danaher's (DHR) Q2 performance, high costs might have impeded the bottom line.

Will Cost Headwinds Dampen Danaher's (DHR) Q2 Earnings?

Danaher is a Dividend Challenger with 8 consecutive years of dividend growth. Shares currently yield 0.39%. Danaher is aggressive with M&A announcing 10 acquisitions totaling more than $10 B in 2021.

Danaher: A Much-Needed Pullback

WASHINGTON , June 29, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher (DHR) gains from solid demand for its products, acquired assets and shareholder-friendly policies. However, escalating costs and high debt levels remain concerns.

Danaher (DHR) Exhibits Bright Prospects, Headwinds Persist

WASHINGTON , June 21, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

News for Danaher Stock (DHR)